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Abstract: Many of malaria’s signs and symptoms are
indistinguishable from those of other febrile diseases.
Detection of the presence of Plasmodium parasites is
essential, therefore, to guide case management. Improved
diagnostic tools are required to enable targeted treat-
ment of infected individuals. In addition, field-ready
diagnostic tools for mass screening and surveillance that
can detect asymptomatic infections of very low parasite
densities are needed to monitor transmission reduction
and ensure elimination. Antibody-based tests for infection
and novel methods based on biomarkers need further
development and validation, as do methods for the
detection and treatment of Plasmodium vivax. Current
rapid diagnostic tests targeting P. vivax are generally less
effective than those targeting Plasmodium falciparum.
Moreover, because current drugs for radical cure may
cause serious side effects in patients with glucose-6-
phosphate dehydrogenase (G6PD) deficiency, more infor-
mation is needed on the distribution of G6PD-deficiency
variants as well as tests to identify at-risk individuals.
Finally, in an environment of very low or absent malaria
transmission, sustaining interest in elimination and
maintaining resources will become increasingly impor-
tant. Thus, research is required into the context in which
malaria diagnostic tests are used, into diagnostics for
other febrile diseases, and into the integration of these
tests into health systems.
Introduction
As malaria transmission declines across much of its range and
the possibility of elimination (reduction of transmission to zero in a
defined geographical area) is increasingly considered [1,2],
accurate diagnosis and case identification through the demonstra-
tion of malaria parasites in sick patients presenting to health
workers (‘‘passive case detection’’) is ever more important. During
case management in all settings, all symptomatic patients with
demonstrated parasitemia should be considered to be malaria
cases, and all parasitemic patients should be given definitive
antimalarial treatment. Accurate diagnosis is essential both to
target antimalarial drugs and to enable effective management of
the frequently fatal nonmalarial febrile illnesses [3] that share signs
and symptoms with malaria [4–13].
However, the very low levels of transmission now being attained
in many countries present new challenges that will demand new
diagnostic tools and strategies, in particular, a change from passive
case detection to ‘‘active’’ case detection. That is, as the
elimination agenda is increasingly followed [14], improvements
in current field diagnostics (microscopy and rapid diagnostic tests
[RDTs]) for case management and new diagnostics that can detect
very low levels of Plasmodium in the blood of asymptomatic
individuals (and, in the case of P. vivax, in the blood of
symptomatic individuals) who may contribute to continuing
malaria transmission [15–21] will become essential. Furthermore,
novel strategies will be needed to incorporate these new and
improved diagnostics into routine health service activities.
More specifically, to avoid onward transmission, elimination
programsformalaria willincreasinglyneed tofocusondetectingthe
highest possible fraction of infections in the general population
through active rather than passive case detection. This change of
focus will be essential because Plasmodium infections can persist at
low densities for different lengths of time with no significant
symptoms [16,22,23], and, in the case of P. vivax and Plasmodium
ovale, as a latent stage in the liver that is not directly detectable. The
contributions of these unseen reservoirs to the maintenance of
transmission will depend on the success of detection and
management of new cases and the coverage of vector and other
control measures in the area [24,25]. Thus, the usefulness of active
case detection will vary with the epidemiology and health resources
in an area and is itself a subject requiring further research [26].
Countries with successful ‘‘sustained control,’’ (the reduction of
malaria transmission to a locally acceptable and sustained level
through intensive use of vector control and effective case
management) [14], will also need to adjust their diagnostic
strategies as transmission declines to low levels and as they
consider elimination. Importantly, until eradication of malaria (the
reduction of transmission to zero worldwide) is achieved (and
diagnostics therefore no longer required), efforts to eliminate
malaria will continue to require diagnostics strategies as reintro-
duction will remain possible.
This article, which summarizes the deliberations of the malERA
Consultative Group on Diagnoses and Diagnostics, proposes a
research agenda for the tools required for this process; related
articles address broader issues of health service requirements and
case management that will arise from their use [26,27]. Figure 1
shows the position of different diagnostic approaches/tests in
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different stages towards malaria elimination. Given the changing
priorities for diagnoses and diagnostics as transmission reduces, in
our discussion of the research needs for diagnostics, we distinguish
between the two broad but overlapping areas of case management
and surveillance/screening. This distinction is reflected in the
target product profiles presented in Table 1. In both areas,
sustainability will require integration with the general health
system, and as much commonality as possible between diagnostics
for different diseases. Thus we discuss priority setting in the
context of the approaches already in use, or in the pipeline, for
other diseases managed at the same levels of the health system.
Because P. falciparum and P. vivax are the most prevalent plasmodia,
the following discussion concentrates on these species, which most
commonly present as mono-species infections. However, as P.
falciparum infections decline, P. ovale may become relatively more
prominent in areas where it is endemic, with implications for
detection and management similar to those for P. vivax. Similarly,
only time will tell whether transmission of Plasmodium malariae,
which is transmitted across a broad geographical range, but at
low prevalence, can be reduced using the measures applied to
P. falciparum, or whether it will require specific strategies and tools.
Notably, however, elimination of the zoonotic Plasmodium knowlesi
is likely to require unique strategies (Figure 1).
Diagnostic Strategies for Programs in the
Intensified Control Phase
Identification of parasitemia in febrile patients is essential in all
of the programmatic phases of the continuum from malaria
control to elimination, although the challenges for health systems
in maintaining this activity in areas where malaria has become
rare will be more prominent, as will the importance of detecting
asymptomatic infections of low parasite density. The ongoing role
of other routine interventions, such as intermittent preventive
treatment in pregnancy, needs reevaluating as elimination is
approached. Moreover, because the distribution of malaria
transmission is often highly heterogeneous within a country,
strategies may need to vary at a subnational level. Analyses of past
experiences and operations research are required to guide
decisions on when these changes in emphasis should take place
as control progresses [27,28]. Although programs in areas of
higher transmission will be less likely to engage in active case
finding of individuals with low parasite densities, surveillance is
nevertheless necessary to detect trends and the impact of
interventions, and requires appropriate, high-throughput diagnos-
tic tools. In addition to the diagnosis of malaria, it will be critical to
have diagnostic capabilities for other causes of presenting illness,
particularly fever. A sick adult or parent of a febrile child may not
be satisfied with a diagnosis of ‘‘not malaria,’’ and both patients
and providers require guidance on the integrated management of
childhood illnesses, to ensure that appropriate alternative and
specific treatment is available and provided.
Summary Points
N New and improved screening tools and strategies are
required for detection and management of very low-
density parasitemia in the field
N Improved quality control is required for rapid diagnostic
tests (RDTs) and microscopy in the field, to ensure
confidence in diagnosis for case management
N More sensitive tests are required for Plasmodium vivax
for case management
N Field-ready glucose-6-phosphate dehydrogenase (G6PD)
deficiency tests and strategies for use to allow safe use
of drugs against P. vivax liver stages are needed
N New strategies to manage parasite-negative individuals
are needed to justify the continued inclusion of malaria
diagnostics in febrile disease management in very low
transmission areas.
Figure 1. The position of different diagnostic approaches/tests in relation to morbidity, parasite prevalence, densities, and
different stages towards malaria elimination. Image credit: Fusio ´n Creativa.
doi:10.1371/journal.pmed.1000396.g001
PLoS Medicine | www.plosmedicine.org 2 January 2011 | Volume 8 | Issue 1 | e1000396Experience in eliminating malaria and maintaining elimination
(or very low transmission) in sub-Saharan Africa is lacking, but
experience from other areas suggests that resource requirements
may be prohibitive and long-term maintenance of very low
transmission and prevention of rebound unachievable using
conventional management [29,30]. Innovative approaches are
therefore required. Diagnostic tools capable of detecting very low
parasite densities (1 parasite/ml blood) in asymptomatic individuals
Table 1. Target product profiles for malaria diagnostics.
Characteristic Case Management in Elimination Settings Screening/Surveillance (District Level or Below)
Technical specifications
Analytic sensitivity (parasite/ml)
a E, 100–200, D,5
b E=20,D#5
Diagnostic sensitivity
a E.95%, D$99% E.95%, D$99%
Analytic specificity Negative all pathogens,
common blood disorders
Negative all pathogens,
common blood disorders
Diagnostic specificity E.90%, D.95% E.99% surveillance low-transmission areas, E.95% screening
Temperature stability E.35uC, D.45uC
c (2 y) E, 30uC; D, 45uC for short periods
Integrity of packaging E, Moisture proof E, Moisture proof
Species detection/differentiation:
Pf predominant areas
d E, Pf; D, Pf/pan E, Pf; D, Pf/pan
Pf and non-Pf areas E, Pf/pan E, Pf/pan; D, differentiation all species
Genotyping No No/O
e
Ability to detect gametocytes No O
Ability to detect hypnozoites No D
Health systems and technical specifications
Packaging of tests or reagents
f D, individual; D, all required
consumables enclosed; D, bulk
packaging displays temperature violations
D, all required consumables enclosed; D,
bulk packaging displays temperature violations
Field stability/shelf life of consumables
g E, 2 y from manufacture
($18 mo in country)
E, 12 mo (6 mo since country); D, 2 y
from manufacture ($18 mo in country)
Training requirements D, half-day of community-level health worker D, ,1 wk of pretrained medical technician
Reagent requirements E, nontoxic, all nonroutine provided; D,
all necessary consumable items to
perform the test provided in the kit
E, nontoxic, all nonroutine provided; D, all necessary
consumable items to perform the test provided in the kit
Invasiveness E, finger prick or less; D, noninvasive E, finger prick or less; D, noninvasive
Rapidity of results
h E#30 min; D#15 min E#2d ;D #half-day
Ease of use Community: E, simple, few steps;
Clinic: E, within medical tech ability; D,
simple, few steps
E, within medical tech ability; D, simple, few steps
Cost D#US$1 per test D#US$1 per test
Safety E, high blood safety with basic
universal precautions
E, high blood safety with basic universal precautions
Waste disposal Village-level waste disposal Basic health system waste disposal
Inter-reader reliability (clarity of result) Kappa.0.9 Kappa.0.9
Instrumentation and laboratory
infrastructure requirements
E, no external power source; D,
all provided with test
D, all provided with test
D, desirable; E, essential; O, optional.
aAnalytic sensitivity: detection threshold against the marker of the infective agent (target) in controlled conditions. Diagnostic sensitivity: proportion (percent) of target
cases detected by the test in the setting of intended use. The sensitivity required for P. vivax is generally at least that required for P. falciparum, and the parameters
here should be applied to both. To achieve the required diagnostic sensitivity in low-prevalence settings, a greater analytic sensitivity (lower threshold of detection)
may be required in some cases.
bNot required for febrile case management, but in an elimination setting, it would be desirable to detect incidental parasitemia at this level.
cEssential where stored in the field in ambient temperatures that frequently reach this level. Ambient temperature of prolonged storage in place of use should be
considered the essential temperature stability requirement for a particular product.
dAreas in which infections are almost exclusively monospecies or mixed species P. falciparum infections. It is likely that many such infections have subpatent
coinfections with other species. Where this represents a minority of infections, treatment on the basis of P. falciparum alone is likely to be acceptable from a
programmatic and public health point of view. Non-P. falciparum infections are likely to become relatively more prominent as P. falciparum infections decline in
prevalence, making the detection of non-P. falciparum species more desirable.
eMay be of importance in areas undergoing certification for elimination.
fAll inner (individual test) packaging should display, at a minimum: manufacturer name, product name, expiry date, lot number, target use (malaria).
gOutcome of temperature stability and integrity of packaging (ability to exclude moisture).
hRapidity of results: For case management, results must be available before a patient is likely to leave the clinic. For surveillance, result availability in time for finding and
managing cases is highly desirable.
doi:10.1371/journal.pmed.1000396.t001
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population surveillance to obtain a true picture of the prevalence
of parasitemia and probability of transmission (as distinct from
symptomatic malaria) [16–21]. Active case detection and treat-
ment will be required whenever ongoing transmission is suspected
and in high-risk populations (including those crossing borders), if
the likelihood of ongoing transmission is to be eliminated. In these
circumstances, test specificity is of increased importance because
the absence of false positive results is critical in understanding the
presence or absence of transmission [26].
Diagnostic Strategies for Programs in Areas
Where Elimination Has Taken Place
Once malaria is eliminated in a given area, considerable
resources will be required to detect reintroduction through
surveillance and to maintain capacity for rapid management and
investigation of any cases found, as long as the risk factors that
support transmission are still in place. Screening of migrant
populations, screening of populations around detected cases, and
case management tools for screening suspected patients, such as
recent travelers or geographical associates of malaria cases may be
needed. The tools to achieve these activities must be readily
available in an environment where technicians are likely to be
unskilled in the use of malaria diagnostic tests, particularly
microscopy [27]. Thus, the requirements for surveillance and
screening in areas where malaria has been eliminated, but risk of
transmission is present, are similar to those of programs in an
elimination phase. However, case management tools that are
minimally dependent on previous technician experience in
diagnosing malaria will be of particular importance.
Diagnostic Tools for Case Management in an
Elimination Setting
In settings where there is risk of autochthonous or imported
malaria, diagnostics must be capable of rapidly and accurately
detecting and quantifying parasitemia in febrile patients, and
identifying species. In addition, highly sensitive diagnostic tools are
needed for passive case detection and case management at health
care facilities (public or private) that report to the national health
information or disease surveillance systems. The issues around
diagnostics in both case management and surveillance and control
settings have a large impact on, and are impacted by, monitoring
and evaluation requirements and health systems implementation
issues such as the development of improved supply lines and
logistics management, reporting of results and commodity
consumption, and adherence of health workers and patients to
management consistent with diagnostic results. These are all
important areas where pooling of knowledge and sometimes
operational research is required to maximize the impact of the
diagnostic tools discussed below [26,27].
Light Microscopy
When performed to a high standard, light microscopy is capable
of accurately identifying and quantifying Plasmodium parasites with
sufficient rapidity for case management in most settings. It remains
the operational gold standard in both control and elimination
settings. However, the quality of light microscopy in the field is
often inadequate [31–36] and limited by factors such as the
instability and difficult preparation of currently used Roma-
nowsky-based stains [37–39], poorly maintained, low quality
equipment, and inadequate training, supervision, and quality
assurance. Additionally, as malaria transmission decreases, it is
likely that light microscopy technician skills may be redeployed
elsewhere. Consequently, research into sustainable ways to
maintain high-quality light microscopy in field settings, including
innovative training, supervisory, and quality-assurance systems, is
badly needed. More consistent and stable staining techniques are
also required. This area of research has been ignored for the past
60 to 100 years, but has the potential to improve field accuracy
significantly and may also improve the potential of the new
reading techniques discussed below. Large volumes of slides pose
particular challenges with respect to reading, especially in settings
with low parasite prevalence where microscopist performance is
hard to maintain [26].
Digital Microscopy
Computer-assisted analysis of Giemsa-stained slides (possibly
combined with automated staining), or digitized image transfer
(potentially via mobile telephone) to a reference centre for review by
an expert microscopist may enable greater consistency in parasite
detection [40–44]. Additional research is required to determine
whether these techniques will detect lower parasite densities than
can be obtained by traditional light microscopy. Related techniques
under development use software analysis of the scatter of various
wavelengths of light to identify Plasmodium parasites and other
pathogens. Although these digital techniques have the potential to
improve field detection of malaria parasites, field-ready versions are
not yet available, and it is not known whether these tools will meet
the requirements for use in resource-poor settings.
Fluorescent-Assisted Microscopy
Fluorescent-assisted microscopy (FAM)-based methods—for
example, the quantitative buffy coat (QBC) method [45],
incorporation of a fluorescent probe (fluorescence in situ
hybridization [FISH]) or of parasite DNA [46], or antigen
staining—has been used to a limited extent in various programs.
FAM methods may eventually speed up slide reading and reduce
operator error. High-throughput FAM may become possible if
high specificity can be maintained by the absence of low artifactual
staining. However, at present FAM cannot differentiate between
species, a capability considered a major advantage of light
microscopy over today’s antigen-detection tests, although spe-
cies-specific markers for FISH assays and fluorescent-tagged
monoclonal antibodies are being developed. In addition, the
applicability of FAM to parasite quantitation is not clear and FAM
requires specialized equipment that will limit where it can be used.
Antigen-Detecting RDTs
RDTs based on the detection of specific parasite antigens that
use a platform design of lateral immunochromatographic flow
(dipsticks or plastic cassettes) have started to change the way
malaria is diagnosed in endemic settings. RDTs are increasingly
being used at the community level and in control programs for
case management and in prevalence surveys. Good RDTs reliably
detect parasitemia down to 100–200 parasites/ml, which is
comparable to the sensitivity of routine well-performed light
microscopy [47]. In general, RDTs are simple to use. With
training and quality assurance, they can be used by peripheral
facility and village health workers to determine whether malaria
parasites are present in a patient. However, increasing use in field
settings suggests that many commercial RDTs have variable
detection thresholds and field stability [48]. Systems for monitor-
ing performance and routine quality control of manufactured
product lots are therefore required.
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RDTs. Histidine-rich protein 2 (HRP2)-detecting tests have high
sensitivity and specificity for P. falciparum but detectable antigen
frequently persists after parasite clearance. The presence of HRP2
deletions in areas of South America also limits the use of these tests
[49]. Commercial tests for Plasmodium lactate dehydrogenase
(pLDH) have yielded variable results and, in general, have less
potential to detect low parasite densities and greater susceptibility
to deterioration under storage at high temperature than HRP2-
based tests [48,50]. However, species-specific (P. falciparum and
P. vivax) and pan Plasmodium species-specific pLDH-based tests are
available. Finally, tests targeting pan-specific parasite aldolase
have shown inadequate detection thresholds in recent comparative
trials, possibly because of the low concentrations of this target
antigen in parasites [48].
The development of RDTs targeting other antigens may improve
species identification (critical for elimination of P. vivax) and address
some of the deficiencies of the current RDTs. In particular, current
tests for P. vivax, which lack consistency in sensitivity and stability,
might benefit from the use of monoclonal antibodies that target new
antigens or improved manufacturing standards.
Quality-Control Methods for Malaria RDTs
Standardized quality-control methods for RDTs are important
for confirming test quality and ensuring that health workers and
patients trust results. As with microscopy [39], quality assurance of
RDTs requires a comprehensive, organized program [47,51].
Such programs are absent in many countries. The development of
standardized panels containing known concentrations of target
antigens will greatly broaden the reach, applicability, and
sustainability of RDT quality-control programs. Parasite-based
panels that use cryo-preserved parasite preparations [52] are
currently available at a centralized (regional) level, but panels that
are easier to standardize and widely available are needed.
Likewise, standardized regulatory approval and procurement in
keeping with best practices will reduce the requirement for
investment by individual procurement agencies in quality control
and product evaluation programs. The development of low-cost
tools for confirming quality at the national and field level (positive
controls [53]) is also necessary to improve reach and sustainability.
Finally, novel approaches that use PCR to confirm RDT results
might eventually be useful.
Diagnostic Tools for Active Case Detection and
Community Surveys
For use in active surveillance and case finding, a diagnostic tool
must be suitable for use in resource-poor field settings. Diagnostic
tests must therefore be supportable at the district level or below, be
affordable and low-maintenance, require less operator training
than current methods, and have a low requirement for
consumables. They should also detect very low parasite densities
and distinguish between all locally prevalent Plasmodium species, be
minimally invasive, and provide sufficiently rapid results to
facilitate effective case management when an infection is identi-
fied. For use in prevalence surveys, where immediate management
of asymptomatic parasitemia is not the aim, testing at a more
centralized level may be sufficient. But, even in this context, rapid
feedback and case management are desirable.
Molecular (DNA) Detection
Current methods of detecting circulating parasites by demon-
strating parasite DNA through amplification of ribosomal RNA
(rRNA) genes by PCR assays represent the overall gold standard of
malaria diagnostics. When sample concentration methods are
used, 0.5 parasite/ml unconcentrated blood or lower can be
detected. Quantitative PCR can be used to determine the
concentration of circulating DNA and therefore estimate the
density of circulating parasites. Survey and testing techniques,
including pooling of samples, can reduce costs [54] but also reduce
sensitivity to some extent by diluting samples.
At present, the application of PCR-based methods is restricted
to well-equipped laboratories with specially trained technicians,
partly because the need to avoid contamination (which leads to
false-positive results) requires a very high standard of laboratory
practice. PCR capacity is consequently limited in resource-poor
malaria-endemic countries, where considerable investment would
be required to establish and maintain it. PCR capacity-building
programs are underway in several African countries through the
Malaria Clinical Trials Alliance (MCTA). However, its restriction
to well-equipped laboratories limits the applicability of PCR for
surveillance and asymptomatic parasitemia case finding because
timely feedback to allow the treatment of identified cases is
impossible in most endemic areas. The development and field
demonstration of high-throughput field-applicable PCR technol-
ogies is therefore needed to allow wider use of PCR in endemic
settings.
Another molecular detection method based on DNA amplifi-
cation is loop-attenuated isothermal amplification (LAMP). This
method, which amplifies DNA (usually mitochondrial) with a
single thermal cycle, has the potential to reduce the training and
infrastructure requirements of molecular diagnosis [55–57], and
would allow the timely feedback of results needed for case
management. LAMP could also be used for surveillance, for
detection of low-density parasitemia, and for monitoring parasite
presence in antimalarial drug-efficacy monitoring and drug trials.
However, LAMP has not yet been adequately field tested for wide-
scale use or developed in a format suitable for the processes of high
sample numbers.
Hemozoin Detection
Hemozoin, a by-product of Plasmodium metabolism, can be
detected through refraction/absorbance of laser light of certain
frequencies, and has been used to detect malaria and to determine
species. Current field-ready technologies are based on flow
cytometers. Their application is limited to screening, however,
because of low sensitivity at low parasite densities [58–62].
Current research activities include the development of transcuta-
neous hemozoin detection. If sufficiently sensitive and specific, this
approach might offer a noninvasive test for malaria for mass-
population screening of, for example, individuals moving into a
malaria elimination area. Hemozoin detection may find a place in
routine case management if appropriate tools can be developed.
Antigen-Detection Tests
Current antigen-detecting RDTs (see earlier for details) are
likely to miss a significant proportion of asymptomatic cases in
low-transmission settings [16,22,23,39]. Thus, although the
current generation of RDTs can indicate the presence of malaria
in a community, they cannot determine the true prevalence of
parasite carriage. Research aimed towards increasing the sensitiv-
ity of existing RDTs may not change this situation because of the
limitations of the currently available technology. Some antigen-
detecting ELISAs are more sensitive than RDTs. Furthermore,
because they can also be used to quantify antigen, they have been
used to monitor drug efficacy. Antigen-detecting ELISAs may also
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limited by laboratory and training requirements.
Antibody Detection
Antibody detection (see also [27]) is currently available in
ELISA and RDT formats, and is a sensitive way to demonstrate
past exposure to malaria parasites (past infection). Because
antibodies may not be detectable in blood-stage infections of very
recent onset, these tests are inappropriate for case management.
However, they may be useful in detecting established P. falciparum
infections in which the blood-stage parasite density has fallen
below the limits of light microscopy or antigen-detecting RDTs
[63]. Detection of antisporozoite antibodies (so-called anti-CSP
antibodies) alone or in combination with antibodies to blood-stage
parasites has also been suggested as a surrogate for detecting
individuals with a high likelihood of carrying P. vivax hypnozoites
(evidence of infection) [64–68]. However, anti-CSP antibody
responses are usually low and transient, especially in areas of low
and moderate transmission, which renders this test unreliable.
Because antibody-detecting tests can identify parasite-infected
individuals who are undetectable by antigen detection or light
microscopy because of low parasite density, they could be used to
screen populations such as migrants or blood donors to identify
asymptomatic individuals at risk of transmitting malaria. They
could also be used for identifying foci of recent transmission in
areas that are otherwise malaria free and to determine the
presence or absence of recent malaria transmission in specific
populations, such as young children. They therefore have potential
applications in confirming areas free of transmission during a
defined period, provided they are further refined and developed in
terms of sensitivity and specificity.
Specific Issues for Reduction and Elimination of P.
vivax Transmission
Detection of Hypnozoites
P. vivax detection and management will become increasingly
important as control measures reduce P. falciparum transmission. In
many programs, P. vivax already causes the majority of clinical
malaria episodes. Because P. vivax can remain latent in the liver but
produces relapse, its effective management normally requires the
use of 8-aminoquinolones to clear hypnozoites from the liver. No
current diagnostic technique is capable of detecting P. vivax
hypnozoites, and none are in development, although tests that can
detect the presence of hypnozoites are a key research and
development need wherever and whenever elimination has a
chance of becoming a realistic goal. While symptomatic cases of
P. vivax can be assumed to harbor liver stages and managed
accordingly, a method for detecting hypnozoites would enable
populations in P. vivax-endemic areas to be screened during the
nontransmission season for asymptomatic individuals likely to have
relapses who could then be treated before they become
symptomatic and transmit in the following transmission season.
Screening could therefore reduce the use of 8-aminoquinolones in
mass-treatment programs in P. vivax-endemic areas, which would
reduce the probability of drug-related severe side effects in
glucose-6-phosphate dehydrogenase (G6PD)-deficient individuals
(see next section). At present, compliance issues with the long
course of primaquine (generally 14 days) have limited the broad
application of this approach, and therefore the need for a
diagnostic test for hypnozoites [24].
Potential biomarkers to detect hypnozoites include direct
markers of metabolic activity, released antigens, markers of host
immune response, and indirect serological markers of other stages
(e.g., sporozoites). A lack of known markers of hypnozoite
metabolic activity and markers of immunity limits the potential
to assess the likely gains from investment in this area, and more
knowledge of the biology of hypnozoites, perhaps through the
development of liver-stage cultures, is required to determine
whether such tests can be developed [69].
Detection of G6PD Deficiency
The only drug currently licensed for the radical cure of P. vivax
infection is primaquine, and the only investigational drug showing
promise is tafenoquine, Both these 8-aminoquinolones cause
hemolysis in G6PD-deficient individuals, the clinical importance
of which varies with the particular G6PD-deficiency phenotype,
and the starting hemoglobin concentration, and may depend on
how the drugs are administered [70].
Because eliminating P. vivax reservoirs will probably involve the
use of a hypnozoiticidal drug [24], unless a non–8-aminoquino-
lone drug is developed, G6PD testing is likely to be required for
wide-scale elimination of P. vivax. The requirements for such a test
differ somewhat from those of parasite-detecting RDTs, because
testing should only be required once in a lifetime and is not
urgently required; the use of hypnozoiticidal drugs can be delayed
if necessary. So, for example, a G6PD test does not have the
stability requirements of an antigen-detecting RDT. Current tests
for G6PD deficiency nevertheless have limitations regarding
storage requirements and the complexity of the procedure, so
research is needed to develop new tests. Importantly, addressing
G6PD deficiency will also involve research into test implementa-
tion—how should samples be tested, where should tests be done,
and how should results be recorded to facilitate retrieval? More-
over, to decide whether further development of field-applicable
G6PD tests is needed also requires more data on the distribution of
G6PD phenotypes and on the efficacy and safety of alternatives to
the standard hypnozoiticidal primaquine regimen.
Other Research Priorities for Future Malaria
Diagnostics
Noninvasive Sampling
Current RDTs detect antigen in peripheral blood samples
obtained by finger prick. This method is generally acceptable for
case management in the formal health care sector, but it presents
some logistical challenges at the community level and in some
private sector settings, particularly with regard to the potential
risks of blood-borne infection. In addition, invasive tests may not
be fully accepted in some settings, particularly when taking
samples from asymptomatic individuals, which could diminish
access to malaria diagnosis, treatment, and surveillance. Nonin-
vasive sampling (for example, saliva or urine collection) has the
potential to overcome these impediments but, at present, the
limitations of sensitivity of nonblood sampling are even greater
than the limitations of blood sampling combined with antigen-
detecting RDTs for screening and surveillance [71–73]. Published
trials of antigen sampling from saliva and urine, for example, have
demonstrated inadequate sensitivity, probably because of the low
concentration of available antigen in these samples [71,74]. Urine
sampling may also present practical and cultural constraints.
Techniques that concentrate antigen may have potential if they
can be made practical for use in low-resource settings, but no such
techniques are currently available. Additionally, if quantification is
required, these methods would need to incorporate a standard to
allow for variations in concentration of saliva or urine.
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Multiple diagnoses from one assay or ‘‘multiplexing’’ is made
possible by, for example, the inclusion of multiple PCR-based
nucleic acid probes in a single test or the inclusion of antibodies
specific for nonmalarial diseases or of pathological markers of
disease severity. The inclusion of antibodies targeting nonmalarial
diseases in RDTs in their common format (visually read
immunochromatographic tests) increases the technical challenge
of achieving the stability needed for sufficient shelf life and makes
interpretation of results more complex. The usefulness of such tests
is also limited by the ability of the health system to provide
appropriate management for each etiological agent that may be
identified, and the highly variable prevalence of potential target
differential diagnoses within malaria-endemic areas.
However, as malaria rates drop through successful control
programs, the overall fever rate may not change significantly.
Accordingly, it will be increasingly important to integrate
management of malaria with that of other febrile diseases, at the
point of diagnosis, if the program is to remain credible and
sustainable (see also [27]). Nonmalarial fever will need to be
diagnosed with sufficient accuracy to allow practitioners to
manage the main causes of fever successfully and to at least
distinguish major bacterial infections manageable with common
antibiotics from nonbacterial infections.
Research and development needs for multiplexing include the
development of field-ready multiplex tests for malaria and non-
malarial diseases, which are not currently widely available, and
research into the inclusion of markers for inflammation or severe
disease in malaria tests, which would offer the potential to guide the
referral of patients who require urgent management (see also [27]).
Finally, the issue of complexity of interpretation in multidisease
diagnostics needs to be addressed by the development of automated
readers, particularly in combination with technology that allows
multiple distinguishable markers to be captured in a single test line.
Pooling Samples for Surveillance, Gametocyte Detection,
and Genotyping
Three other potential research priorities were discussed by the
Consultative Group, but the consensus was that research into
pooling samples, gametocyte detection, and genotyping was less
Box 1. Summary of the Research and Development Agenda for Diagnosis and Diagnostics
Overarching questions
N What proportion of effort should be directed to screening
and surveillance versus early case detection at various time
points in elimination? Question to be addressed by
modeling and validated in different areas.
N Do we need microscopy for elimination, or can other tests
replace it?
Programmatic issues
N Further data on thresholds of (i) parasite density likely to
cause symptoms in low-transmission settings with variable
or waning immunity, and (ii) transmission potential of
cases with parasitemia below the threshold of microscopy
and RDTs
N Diagnostic tests for nonmalarial febrile illness in malaria-
endemic and malaria-elimination settings
N Distribution of severe G6PD variants
Technical issues: case-management tools
High priority
Stable tests for case management in low-training, low-
technology settings with sensitivity sufficient for community-
level case management, including:
N Antigen-detecting RDTs
N Greater consistency in P. falciparum detection, particu-
larly in the case of nonpersistent antigens
N More sensitive and stable tests to detect non-P.
falciparum parasites
N Clarification of the programmatic/implementation re-
quirements that will ensure good impact in the field
N Standardized low-cost positive controls for antigen-
detecting RDTs suitable for field use
N Sustainable tools for quality control of RDTs at a country
level.
N Further investigation of nonblood sampling to determine
the potential for detecting recoverable antigen in these
samples.
N More consistent, reliable staining methods for microscopy
N G6PD deficiency mapping and identification (if 8-amino-
quinolones are to be used)
Medium priority
N Multiplexing: Other diseases, markers of severity
N Field G6PD detection (may be more important if tafeno-
quine approved), or raised priorities for P. vivax relapse
prevention
N Tools to standardize and improve microscopy interpreta-
tion
Low priority
N Hypnozoite detection (becomes a high priority if feasibility
can be demonstrated through further research on
hypnozoite biology, identifying good biomarkers).
Technical issues: surveillance tools
High priority
N Field-applicable tools for detection of low-density parasit-
emia in a high-throughput manner, suitable for surveys
and active detection of parasite carriage in time to allow
management of positive cases
N Tools for minimally invasive, very rapid detection of low-
density parasite infections suitable for screening of
migrants/travelers
Innovation with potential for major operational impact
N Noninvasive, low-density parasite detection
Low-hanging fruit with immediate application for
elimination
N High-throughput field molecular detection, capable of use
at district level or below
N Positive control methods for RDTs
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detect parasitemia in very low transmission settings is intrinsically
appealing and could result in cost savings using currently available
tests, the Consultative Group felt that the limited quantity of
antigen or DNA in pooled samples would severely limit the
sensitivity of this approach. Similarly, the group decided that the
development of a detection test for gametocytes should not be
viewed as a high priority requirement. Finally, although WHO
guidelines recommend genotyping of parasites during elimination
phases [39], there is debate about whether research into methods
for genotyping would be programmatically useful, particularly for
P. falciparum. The resource needs to achieve genotyping are
massive, and the long feedback time for results is likely to reduce
the exercise to one of academic interest only. Genotyping could be
useful for P. vivax infections to determine whether a blood-stage
infection is new or a relapse. However, it has not yet been possible
to develop methods that will reliably distinguish between relapse,
recrudescence, and reinfection because of the multiplicity of
hypnozoite genotypes present in P. vivax-infected individuals.
Genotyping might, however, be useful in suspected outbreak or in
new foci of transmission to determine the source of parasites,
particularly when elimination in an area is being confirmed [26].
Sustaining the Effort
The central importance of active case detection in each
programmatic stage towards elimination has been comprehen-
sively dealt with by several of the other malERA Consultative
Groups [24–27]. However, whether active case detection can be
achieved at sufficiently high and sustainable levels will depend to a
great extent on the field utility and costs of the diagnostic and
other tools eventually adopted for this role and on how these tests
are used.
Importantly, when malaria is rare and no longer perceived by
local health services and the community to be of significant public
health concern, ways must be found to maintain the resources
needed to test febrile cases for parasitemia to prevent resurgence of
infection. Because malaria parasite detection will be competing for
resources with other disease priorities with higher mortality, it will
be necessary to target diagnostics to those cases more likely to be
malaria rather than necessarily screening whole populations
(although some form of screening, and the ability to respond
rapidly to reintroduction, will continue to be necessary [26–28]. It
will also be important to integrate malaria detection more fully
with other health service activities and, as nonmalarial causes of
fever become predominant, it will be critical to provide appro-
priate diagnosis and management of alternative causes so that
compliance is maintained through confidence in the ability of the
health system to provide solutions to clinical problems.
Conclusions
Malaria elimination in the most challenging settings will require
improvements in point-of-care tests for case management, and the
development of new tests capable of identifying very low parasite
densities in asymptomatic individuals in field settings for mass
screening and treatment. As a result of our discussions, we propose
a research and development agenda for diagnoses and diagnostics
that should stimulate and facilitate the development, validation,
and use of such tests (see Box 1).
Because malaria generally occurs in low-resource settings, the
profits likely to be made from malaria diagnostic development and
manufacture, particularly in the face of low mortality, are limited.
The current market place for malaria rapid tests is dominated by
small to medium-sized manufacturers, who are unlikely to be able
to make the major investments needed to address these priorities
alone. Thus, the role of donor agencies and product development
partnerships and research institutions in enabling research and
development and in providing the expertise and field access
necessary to shape products to meet program needs will be an
essential element of diagnostics development. Critically strong and
focused, mainly public-private, partnerships will need to built and
nurtured.
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